This segment focuses on the research and development of oral therapies designed to protect and restore the integrity of the gastrointestinal (GI) tract. The primary focus is on developing therapeutics for conditions such as ulcerative colitis (UC) and Crohn's disease. Research and development activities include preclinical studies, clinical trials, and the development of novel drug formulations. The company utilizes technologies such as protease inhibitors and prodrugs to target specific areas of the GI tract. The goal is to improve patient outcomes by reducing inflammation, promoting healing, and preventing complications associated with GI disorders. Market positioning involves targeting unmet medical needs in the inflammatory bowel disease (IBD) space. Competitive advantages include a focus on oral delivery and targeted drug action. Future opportunities include expanding the pipeline with additional GI-focused therapies and exploring partnerships to accelerate development. Regulatory and clinical aspects involve navigating FDA approval processes and conducting clinical trials to demonstrate safety and efficacy. Collaborations with research institutions and pharmaceutical companies are pursued to enhance drug development efforts.